Key Highlights

• Walmart has settled a Department of Justice lawsuit alleging the company unlawfully filled invalid opioid prescriptions, contributing to the US opioid epidemic.

• The lawsuit, originally filed in December 2020, accused Walmart of pressuring pharmacists to Fill prescriptions quickly rather than following legal screening requirements.

• Terms of the settlement were not immediately disclosed, though court filings confirmed the federal government agreed to dismiss the case.

• The settlement follows a separate $3.1 billion agreement Walmart reached with US states in 2022 over similar opioid-related claims.

A Long-Running Legal Dispute Comes to a Close

Walmart (NYSE:WMT) has reached a settlement with the US Department of Justice resolving a lawsuit that accused the retailer of unlawfully filling opioid prescriptions and contributing to the nation's opioid crisis. The Justice Department confirmed the settlement, though specific financial terms were not immediately made public. Court filings showed that the federal government agreed to dismiss the case as part of the resolution.

A Justice Department spokesperson said the agency remains committed to enforcement in this area, stating that it will continue to hold accountable companies and individuals whose unlawful prescribing, marketing, dispensing, or distributing practices contributed to the opioid crisis and put American communities at risk. Walmart did not immediately respond to a request for comment on the settlement.

Origins of the Case

The lawsuit was originally filed in December 2020, with the government alleging that Walmart filled invalid prescriptions and failed to report suspicious orders for opioids and other controlled substances. The case followed a multiyear investigation by federal authorities. According to the lawsuit, Walmart's internal management practices made it "exceedingly difficult" for pharmacists to comply with legal prescription requirements, allegedly pressuring staff to process prescriptions "as quickly as possible."

Walmart had preemptively sued the Department of Justice and the Drug Enforcement Administration in October 2020, arguing that its pharmacists had been placed in an impossible position by conflicting federal expectations. At the time, the company said it had blocked thousands of prescriptions from what it described as questionable prescribers. That countersuit was dismissed in 2021.

A Costly Legal Exposure Now Resolved

Walmart had faced the possibility of billions of dollars in penalties had the case proceeded to trial and resulted in a finding of liability. The retailer had already resolved a related matter in 2022, agreeing to pay $3.1 billion to settle claims brought by US states alleging the company failed to adequately regulate opioid prescriptions at its pharmacies.

A Broader Pattern of Opioid-Related Settlements

The resolution of Walmart's case adds to a long list of settlements involving major retailers and pharmaceutical distributors tied to the opioid epidemic. Drug overdose deaths in the US rose approximately 520% between 1999 and 2023, according to federal health data, though annual deaths have declined since peaking in 2022. The settlement closes a significant chapter of legal exposure for Walmart tied to its pharmacy operations during the height of the crisis.